|

Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

RECRUITINGSponsored by Duke University
Actively Recruiting
SponsorDuke University
Started2022-05-27
Est. completion2026-11-01
Eligibility
Age18 Years+
Locations1 site
View on ClinicalTrials.gov →

NCT05397132

Summary

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Eligibility

Age: 18 Years+
Inclusion Criteria:

1. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
2. Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
3. Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.

Exclusion Criteria:

* NA

Conditions2

CancerHematologic Malignancy

Locations1 site

Duke University
Durham, North Carolina, 27710
Cristina Gasparetto, MD919-668-1017cristina.gasparetto@duke.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.